This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
by Zacks Equity Research
ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.
Encompass Health Opens First Connecticut Rehab Hospital in Danbury
by Zacks Equity Research
EHC opens its first Connecticut rehab hospital in Danbury, boosting its nationwide expansion and meeting rising demand for specialized care.
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
by Zacks Equity Research
Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study
by Zacks Equity Research
Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.
Powell Warns of Valuation Risks: 5 High Earnings Yield Value Picks
by Rimmi Singhi
Powell flags lofty valuations, but five high-earnings-yield stocks stand out as value picks in a cautious market.
Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience
by Zacks Equity Research
Biotech stocks gain momentum as M&A, AI-driven drug discovery, and new approvals fuel growth; Halozyme, Akero, Kiniska, ANI and Twist stand out.
Halozyme Therapeutics and Synopsys have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Halozyme shines with strong growth and partnerships, while Synopsys struggles after earnings miss and lowered outlook.
5 Biotech Stocks Worth Adding to Your Portfolio Now
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, AKRO, KSNA, ANIP and TWST in this volatile sector
Bull of the Day: Halozyme Therapeutics (HALO)
by Kevin Cook
The Street bailed on HALO in the spring, right before a summer rally to new highs on strong growth
Halozyme Therapeutics (HALO) Is Up 2.63% in One Week: What You Should Know
by Zacks Equity Research
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year?
by Zacks Equity Research
Here is how atai Life Sciences N.V. (ATAI) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
5 High Earnings Yield Stocks to Buy Ahead of Potential Fed Rate Cuts
by Rimmi Singhi
As Fed rate cuts loom, value investors may eye HALO, PARR, BPOP, PHIN and KT - stocks with high earnings yield and growth potential.
Zacks.com featured highlights include Halozyme Therapeutics, Leidos and TransUnion
by Zacks Equity Research
Halozyme, Leidos and TransUnion earn upgraded broker ratings, with earnings growth and positive revisions boosting appeal.
Zacks.com featured highlights include Halozyme Therapeutics, Phibro, Leidos and PDD Holdings
by Zacks Equity Research
Halozyme, Phibro, Leidos and PDD Holdings shine as GARP picks, blending discounted valuations with strong long-term growth potential.
Bet on These 3 Stocks With Upgraded Broker Ratings for Robust Returns
by Swayta Shah
Broker upgrades boost Halozyme, Leidos and TransUnion, each projected for solid 2025 earnings growth and stronger returns.
4 PEG-Rated GARP Stocks That Offer Both Value and Growth
by Urmimala Biswas
Halozyme, Phibro, Leidos and PDD Holdings stand out as PEG-rated GARP picks, blending value and growth with solid long-term potential.
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice
by Zacks Equity Research
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Best Momentum Stock to Buy for September 3rd
by Zacks Equity Research
HALO, TROW and CARS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 3, 2025.
Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?
by Zacks Equity Research
Here is how Halozyme Therapeutics (HALO) and atai Life Sciences N.V. (ATAI) have performed compared to their sector so far this year.
Halozyme Therapeutics, Inc. (HALO) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Halozyme Therapeutics (HALO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.